ClinicalTrials.gg

Program

pemigatinib

Also written as “Pemigatinib”.

Its studies are mostly in Cholangiocarcinoma · Carcinoma, Transitional Cell · Glioblastoma · Neoplasms, Unknown Primary · Myeloproliferative Disorders, led by 3 companies.

Furthest: phase 3, since Aug 29, 201816 company-led studies, 1 open or runningNext primary completion: Feb 25, 2031 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Incyte131 open or runningphase 3since Aug 29, 2018Jan 30, 2015Feb 25, 2031phase 2 · NCT07862998
Innovent Biologics20 open or runningphase 2since Jan 20, 2020Jan 20, 2020none ahead
Hoffmann-La Roche10 open or runningphase 2since Apr 5, 2018Apr 5, 2018none ahead

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jan 30, 2015First study: phase 2 study in Lung NeoplasmsNew to IncyteIncyte · NCT02393248 · 201 enrolled · United States, Denmark
  2. Aug 16, 2016Phase 2 study in Carcinoma, Transitional CellIncyte · NCT02872714 · 263 enrolled · United States, Belgium, Denmark and more
  3. Oct 4, 2016Phase 2 study in CholangiocarcinomaIncyte · NCT02924376 · 147 enrolled · United States, Belgium, France and more
  4. Jan 4, 2017Phase 2 study in Myeloproliferative DisordersIncyte · NCT03011372 · 47 enrolled · United States, Austria, Belgium and more
  5. Jul 27, 2017Phase 1 study in NeoplasmsIncyte · NCT03235570 · 44 enrolled · Japan
  6. Apr 5, 2018Hoffmann-La Roche's first study: phase 2 study in Neoplasms, Unknown PrimaryNew to Hoffmann-La RocheHoffmann-La Roche · NCT03498521 · 529 enrolled · Australia, Austria, Brazil and more
  7. Aug 29, 2018Phase 3 study in CholangiocarcinomaIncyte · NCT03656536 · 167 enrolled · United States, Austria, Belgium and more
  8. Jan 28, 2019Phase 2 study in AcrocephalosyndactyliaIncyte · NCT03822117 · 111 enrolled · United States, Denmark, France and more
  9. Jun 25, 20192 phase 2 studiesIncyte · NCT04003623, NCT04003610
  10. Jan 20, 2020Innovent Biologics's first study: phase 1 study in Solid TumorNew to Innovent BiologicsInnovent Biologics · NCT04258527 · 12 enrolled · China
  11. Jan 20, 2020Phase 2 study in CholangiocarcinomaInnovent Biologics · NCT04256980 · 34 enrolled · China
  12. Jun 25, 2021Phase 2 study in Advanced MalignanciesIncyte · NCT04949191 · 10 enrolled · United States, Denmark, Italy and more
  13. Feb 14, 20222 phase 2 studiesIncyte · NCT05253807, NCT05267106
  14. Oct 2, 2026Phase 2 study in CholangiocarcinomaIncyte · NCT07862998 · 72 planned

Ahead

  1. Feb 25, 2031Primary completion: phase 2 study in CholangiocarcinomaIncyte · NCT07862998

TargetBeta

“An orally bioavailable inhibitor of the fibroblast growth factor receptor (FGFR) types 1, 2, and 3 (FGFR1/2/3), ”NCIt, by rule
“Fibroblast growth factor receptor 2 inhibitor; Fibroblast growth factor receptor 3 inhibitor; Fibroblast growth factor receptor 1 inhibitor”ChEMBL 37, by rule

Other programs on the same three targets

ProgramCompanyFurthest phaseStudies
nintedanibruleBoehringer Ingelheimphase 476
infigratinibruleBridgeBiophase 317
futibatinibruleOtsukaphase 310

Studies

All 16 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07862998Cholangiocarcinoma2Not yet recruitingIncyteFeb 25, 203172
NCT05267106Glioblastoma · United States, Denmark, France and more2TerminatedIncyteDec 17, 202483
NCT05253807Carcinoma, Non-Small-Cell Lung · United States, France, Germany and more2CompletedIncyteAug 16, 20238
NCT04949191Advanced Malignancies · United States, Denmark, Italy and more2TerminatedIncyteApr 11, 202410
NCT04258527Solid Tumor · China1CompletedInnovent BiologicsJul 2, 202012
NCT04256980Cholangiocarcinoma · China2CompletedInnovent BiologicsJan 29, 202134
NCT04003610Carcinoma, Transitional Cell · United States, Austria, Belgium and more2TerminatedIncyteApr 18, 20217
NCT04003623Neoplasm Metastasis · United States2TerminatedIncyteJun 12, 20201
NCT03822117Acrocephalosyndactylia · United States, Denmark, France and more2TerminatedIncyteMar 29, 2022111
NCT03656536Cholangiocarcinoma · United States, Austria, Belgium and more3TerminatedIncyteJul 7, 2025167
NCT03498521Neoplasms, Unknown Primary · Australia, Austria, Brazil and more2CompletedHoffmann-La RocheFeb 14, 2023529
NCT03235570Neoplasms · Japan1CompletedIncyteMar 4, 202044
NCT03011372Myeloproliferative Disorders · United States, Austria, Belgium and more2CompletedIncyteOct 30, 202447
NCT02924376Cholangiocarcinoma · United States, Belgium, France and more2CompletedIncyteFeb 1, 2022147
NCT02872714Carcinoma, Transitional Cell · United States, Belgium, Denmark and more2CompletedIncyteFeb 1, 2022263
NCT02393248Lung Neoplasms · United States, Denmark2TerminatedIncyteDec 17, 2021201

How it is read

Names in the registry

  • “Pemigatinib”, 15 entries
  • “pemigatinib”, 2 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.